But it has been disappointing in that the kind of genetic variation it detects has turned out to explain surprisingly little of the genetic links to most diseases... One issue of debate among researchers is whether, despite the prospect of diminishing returns, to continue with the genomewide studies, which cost many millions of dollars apiece, or switch to a new approach like decoding the entire genomes of individual patients.The
unexpected impasse also affects companies that offer personal genomic information and that had assumed they could inform
customers of their genetic risk for common diseases, based on researchers»
discoveries...